A detailed history of Lazard Asset Management LLC transactions in Recursion Pharmaceuticals, Inc. stock. As of the latest transaction made, Lazard Asset Management LLC holds 642,308 shares of RXRX stock, worth $4.11 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
642,308
Previous 524,158 22.54%
Holding current value
$4.11 Million
Previous $3.93 Million 7.66%
% of portfolio
0.01%
Previous 0.01%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$5.92 - $8.6 $699,448 - $1.02 Million
118,150 Added 22.54%
642,308 $4.23 Million
Q2 2024

Aug 14, 2024

BUY
$7.35 - $10.05 $1.79 Million - $2.45 Million
243,490 Added 86.75%
524,158 $3.93 Million
Q1 2024

May 14, 2024

SELL
$9.13 - $15.52 $831,113 - $1.41 Million
-91,031 Reduced 24.49%
280,668 $2.8 Million
Q4 2023

Feb 14, 2024

BUY
$5.09 - $10.79 $186,675 - $395,723
36,675 Added 10.95%
371,699 $3.66 Million
Q3 2023

Nov 14, 2023

SELL
$6.59 - $15.86 $66,552 - $160,170
-10,099 Reduced 2.93%
335,024 $2.56 Million
Q2 2023

Aug 14, 2023

SELL
$4.56 - $9.94 $1,901 - $4,144
-417 Reduced 0.12%
345,123 $2.58 Million
Q1 2023

May 15, 2023

BUY
$6.42 - $9.64 $1.17 Million - $1.75 Million
181,631 Added 110.81%
345,540 $2.3 Million
Q4 2022

Feb 14, 2023

SELL
$7.16 - $12.7 $1 Million - $1.78 Million
-140,303 Reduced 46.12%
163,909 $1.26 Million
Q3 2022

Nov 14, 2022

BUY
$7.83 - $13.6 $114,341 - $198,600
14,603 Added 5.04%
304,212 $3.24 Million
Q2 2022

Aug 09, 2022

BUY
$5.04 - $9.26 $507,452 - $932,343
100,685 Added 53.29%
289,609 $2.36 Million
Q1 2022

May 13, 2022

BUY
$6.16 - $18.03 $280,526 - $821,086
45,540 Added 31.76%
188,924 $1.35 Million
Q4 2021

Feb 09, 2022

BUY
$16.14 - $21.86 $2.31 Million - $3.13 Million
143,384 New
143,384 $2.46 Million

Others Institutions Holding RXRX

About RECURSION PHARMACEUTICALS, INC.


  • Ticker RXRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 180,480,000
  • Market Cap $1.16B
  • Description
  • Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cav...
More about RXRX
Track This Portfolio

Track Lazard Asset Management LLC Portfolio

Follow Lazard Asset Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Lazard Asset Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Lazard Asset Management LLC with notifications on news.